Menu Search
Equities

Cassava Sciences Inc

PX91:DUS

Cassava Sciences Inc

Actions
  • Price (EUR)20.30
  • Today's Change0.695 / 3.55%
  • Shares traded-1.00
  • 1 Year change-3.47%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 19:06 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.

  • Revenue in USD (TTM)0.00
  • Net income in USD-47.90m
  • Incorporated1998
  • Employees29.00
  • Location
    Cassava Sciences Inc6801 N CAPITAL OF TEXAS HIGHWAYBUILDING 1; SUITE 300AUSTIN 78731United StatesUSA
  • Phone+1 (512) 501-2444
  • Fax+1 (512) 614-0414
  • Websitehttps://www.cassavasciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.